Ruella Lab

CAR T cell therapy has shown strong results against certain cancers, but metabolic exhaustion limits its effectiveness over time. In @CellCellPress, the @MaayanLevyPhD & @ChristophThaiss labs report that a common supplement can fuel CAR T cells to fight cancer more effectively.

Excited to share our new paper in @CellCellPress with @MarcoRuella, led by @Shan_Liu_ and @PuneethGuru_. CAR T cell therapy loses effectiveness over time due to metabolic exhaustion, but we found a surprisingly simple approach to address it. 👇 cell.com/cell/abstract/…

Finally out 📣 Ketogenic diet–derived β-hydroxybutyrate boosts CAR T cell metabolism and function. Congrats @Shan_Liu_ and @PuneethGuru_ ! @MarcoRuella @MaayanLevyPhD @PennMedicine @PennMedCSO @PennCancer @CellCellPress sciencedirect.com/science/articl…

Ha distrutto le cellule tumorali presenti nei topi con la stessa efficacia ma senza attaccare anche quelle sane del sistema immunitario. E' la nuova terapia Car-T, che apre la strada verso futuri trattamenti senza effetti collaterali @Penn @MyUniSR ansa.it/canale_scienza…

A new design for #CARTcells that targets IGHV4-34 on B cell receptors can suppress lymphoma cells in vivo and neutralizes autoimmune #lupus B cells from patients, while avoiding off-target killing of healthy B cells. @MarcoRuella @PennCancer scim.ag/4azTURq

You know it's a big impact when Nature covers a Science journal paper. h/t Ivan J Cohen, Audrey C Bochi-Layec, @LemoineJean6 @MarcoRuella @PennMedicine @ScienceTM nature.com/articles/d4158…

🚨NEW - Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells. 🧵below on why is this important. From Ivan J Cohen, Audrey C Bochi-Layec, @LemoineJean6 @MarcoRuella @PennMedicine @ScienceTM #TCell #CARTCell #immunotherapy science.org/doi/10.1126/sc…

Excited to share our new paper in @ScienceTM introducing CART4-34 targeting the IGHV4-34 B cell receptor to eliminate malignant and autoimmune B cells while sparing healthy B cells. Ivan J Cohen, Audrey C Bochi-Layec, @LemoineJean6 @MarcoRuella @PennMedicine @PennCancer

An in-depth analysis of tissue biopsies from patients with multiple myeloma and CART-associated immune-related adverse events (CirAE) after treatment with commercial BCMA-CART shows that CD4+ CARTs mediate off tumor toxicities and that high CD4/CD8 ratio at apheresis, robust early CART expansion, ICANS, and cilta-cel treatment are independently associated with the development of CirAEs. nature.com/articles/s4159…

An in-depth analysis of tissue biopsies from patients with multiple myeloma and CART-associated immune-related adverse events (CirAE) after treatment with commercial BCMA-CART shows that CD4+ CARTs mediate off tumor toxicities and that high CD4/CD8 ratio at apheresis, robust early CART expansion, ICANS, and cilta-cel treatment are independently associated with the development of CirAEs. nature.com/articles/s4159…

New research finds that delayed toxicities after CAR T cell therapy for multiple myeloma are connected & potentially preventable ft. @JoeFraietta, @jh_noll (@PennMicro), @MarcoRuella, @CohenAd_MMdoc, Luca Paruzzo & @MatthewHoMD (@PennCancer) tinyurl.com/ysd4nsdh

Excited to share our new paper in @NatureMedicine uncovering the role of CD4⁺ CAR T cells in CirAEs after BCMA CAR T therapy. @MatthewHoMD @paruzzol @jh_noll @JoeFraietta @MarcoRuella @CohenAd_MMdoc @PennMedicine @PennCancer nature.com/articles/s4159…

CAR T therapy saves lives. But some myeloma patients develop serious delayed toxicities months later. At #ASH2025, Penn researchers led by Dr. @MarcoRuella revealed why: 👉 CD4⁺ CAR T cells show much stronger Cell Avidity to BCMA than CD8⁺ cells. This enhanced binding boosts tumor killing but also drives on-target, off-tumor toxicities in healthy tissues. Identifying Cell Avidity as the driver allowed the team to spot early warning signs and map a potential way to safely modulate CAR T activity. A major advance toward safer, next-generation CAR T therapies powered by a deeper understanding of Cell Avidity. 🔗Abstract of the research at #ASH2025: meetings-api.hematology.org/api/abstract/v… 🔗Discover more Cell Avidity applications in cell therapy: lumicks.com/application/ce… 🔗Contact LUMICKS to implement Cell Avidity in your research: lumicks.com/contact

Happy Holidays from the Ruella Lab! 🎄✨ As we wrap up the year, we are grateful for the dedication and collaborative spirit that drive our research forward 🧬. Wishing our colleagues and collaborators a joyful holiday season and a healthy, inspiring year ahead ❄️ @MarcoRuella

Excited to see viTToria Biotherapeutics recognized as Startup of the Year at Penn’s Celebration of Innovation — a major milestone for next-generation T-cell therapies and the fight against T-cell lymphomas! @MarcoRuella @PennInnovation @viTToriabio penntoday.upenn.edu/news/penn-cent…

Incredible year for the Ruella Lab at #ASH2025! – 15 abstracts directly from the lab ✨ – 10 abstract awards 🏆 – 3 oral presentations 🎤 Proud of every member of the team for your incredible work — you are the reason behind this success. @MarcoRuella @PennMDForum @PennCancer

#ASH25 Seemingly disparate, delayed toxicities after BMCA CAR T for #multiplemyeloma share a common immune root cause and may be preventable, according to new research led by @jh_noll @MatthewHoMD @JoeFraietta @MarcoRuella @CohenAd_MMdoc. Learn more: spr.ly/60107h2Yp

🔬 Proud of @AlbertoCarturan for his Oral Presentation this morning at #ASH2025 on a newly identified role for IL-5 in regulating CART-associated toxicity and efficacy. @MarcoRuella @PennMedicine @PennCancer 🔗 sciencedirect.com/science/articl…

🌟 Ruella Lab helping shape the physicians of the future! Congrats to @AVitorSouza for the Medical Student & Early Investigator Award at #ASH2025 ! @MarcoRuella @ShanLiu @pennmedicine

🧬 Luca Paruzzo update at #ASH2025 on how CCR5 blockade may help boost CART-BCMA expansion while reducing immune toxicities. Stop by our poster tonight! @MarcoRuella @pennmedicine @PennCancer 🔗 sciencedirect.com/science/articl…